Ventyx Biosciences announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company’s SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences Announces Departure of Chief Financial Officer
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Ventyx Biosciences price target lowered to $14 from $15 at Canaccord
- Ventyx Biosciences price target lowered to $11 from $16 at Wells Fargo
- VTYX Earnings this Week: How Will it Perform?